O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer's disease and related tauopathies: analysis of the patent literature [0.03%]
专利文献中关于O-连接N-乙酰氨基葡萄糖酶抑制剂作为治疗阿尔茨海默病及相关Tau疾病的潜在药物的分析
Jose M Bartolomé-Nebreda,Andrés A Trabanco,Adriana Ingrid Velter et al.
Jose M Bartolomé-Nebreda et al.
Introduction: O-GlcNAcylation is a highly abundant post-translational modification of multiple proteins, including the microtubule-binding protein tau, governed by just two enzymes' concerted action O-GlcNAc transferase OGT and the hydrolas...
Dmitrii V Kalinin
Dmitrii V Kalinin
Introduction: Blood coagulation factor XII (FXII) is an emerging and potentially safe drug target, which dysregulation is associated with thrombosis, hereditary angioedema, and (neuro)inflammation. At the same time, FXII-deficiency is pract...
Ulrich Storz
Ulrich Storz
Introduction: NGOs and governments of some countries have demanded suspension of patents protection of COVID-19 vaccines and the underlying technology to enhance worldwide access. At the same time, companies actually developing and producin...
Marco Zattoni,Giuseppe Legname
Marco Zattoni
Introduction: Prion diseases are a class of rare and fatal neurodegenerative diseases for which no cure is currently available. They are characterized by conformational conversion of cellular prion protein (PrPC) into the disease-associated...
Recent updates on Wnt signaling modulators: a patent review (2014-2020) [0.03%]
Wnt信号调节剂近期专利文献更新（2014-2020）
Vishalgiri G Goswami,Bhumika D Patel
Vishalgiri G Goswami
Introduction: Wnt signaling is a signal transduction pathway that plays a vital role in embryonic development and normal tissue preservation. Dysfunction of it gives rise to various diseases like cancer, Alzheimer's, metabolic and skeletal ...
A patent review of mTOR inhibitors for cancer therapy (2011-2020) [0.03%]
2011-2020年作为癌症治疗的mTOR抑制剂专利回顾
Han-Yue Qiu,Peng-Fei Wang,Min Zhang
Han-Yue Qiu
Introduction: The mammalian target of rapamycin (mTOR) kinase is a central component in the PI3K/Akt/mTOR pathway and plays a crucial role in tumor biology, making it one appealing therapeutic target. In the past decade, ...
Mohd Imran,Alshrari A S,Mohammad Tauseef et al.
Mohd Imran et al.
Introduction: Mucormycosis is an uncommon but life-threatening infection with nonspecific clinical manifestations that make its diagnosis/treatment difficult. The current literature indicates that mucormycosis case incide...
Discerning the promising binding sites of S100/calgranulins and their therapeutic potential in atherosclerosis [0.03%]
辨别S100/角蛋白有希望的结合位点及其在动脉粥样硬化治疗中的潜力
Harbinder Singh,Vikrant Rai,Devendra K Agrawal
Harbinder Singh
Introduction: Atherosclerosis is a chronic inflammatory disease in which the members of S100 family proteins (calgranulins) bind with their receptors, particularly receptor for advanced glycation end products (RAGE) and t...
Thoraya A Farghaly,Wedian A Al-Hasani,Hanan Gaber Abdulwahab
Thoraya A Farghaly
Introduction: Angiogenesis is a vital process for cellular functions in both physiological and pathophysiological conditions and is one of the hallmarks of cancer progression and metastasis. VEGF/VEGFR-2 signaling pathway has been recognize...
Avoiding hindsight in non-obviousness determination: case law review of pharmaceutical patents and guidance from the KSR v Teleflex decision [0.03%]
避免在显而易见性判定中出现事后诸葛亮的情况——源自药品专利案例的启示及KSR诉Teleflex判决的相关指导原则
Sivakami Dhulap,M G Kulkarni
Sivakami Dhulap
Introduction: Hindsight bias is the tendency to estimate an outcome once it is known. Legal systems are often prone to hindsight bias. In patent law, the non-obviousness or inventive step is the most critical determinant of patentability an...